

SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Dated:22/12/2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

SCRIPTCODE:524703

Dear Sir/Ma'am,

<u>Sub: Notice</u> intimating discrepancies by Government Of Maharashtra Department Of Goods And Service Tax-Office Of The Deputy Commissioner of the State of Goa under Regulation 30 of SEBI (lord) Regulation 2015

Pursuant to the provisions of Regulation 30 read with sub-para 20 of Para A of Part A of Schedule III of the Listing Regulations, we are in receipt of notice for intimating discrepancies in the return after scrutiny, passed by Government of Maharashtra Goods & Service tax Department.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully, For. Sandu Pharmaceuticals Limited



Pratika Mhambray Company Secretary and Compliance Officer A36512

Encl:-As Above







SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

ANNEXURE-A	
Name of the Authority	Government Of Maharashtra Department Of Goods And Service Tax-Office Of The Deputy Commissioner Of State Tax
Nature and details of the action(s) taken, initiated or order(s) passed	Notice for intimating Discrepancies in the return passed by Maharashtra Goods & Service Tax Act, 2017. {see Rule 99(1) of the Maharashtra Goods & Services tax Rules,2017}
Date of receipt of direction or order, including any ad- interim or interim orders, or any other communication from the Authority;	22/12/2025
Details of the violation(s)/contravention (s) committed or alleged to be committed;	Notice received for intimating discrepancies with respect to Non reversal of ITC in GSTR3B as compared with GSTR9 of FY2023-24 for Rs.13,00,679/.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The Company shall be filing reply to authority on notice issued to Company. As per Company's own assessment and also based on legal advice, management is confident of favorable outcome for such notice if any. Hence no impact is envisaged on the financials, operations or other activities of the Company on account of the above mentioned Liability.
Remarks	N.A.

For Sandu Pharmaceuticals Limited

Pratika Mhambray Company Secretary & Compliance Officer





